Efficacy and safety of local ablative therapy for patients with NSCLC and coexisting interstitial lung disease.

ABSTRACT:

Background

The effective therapeutic approach is still an unmet need for patients diagnosed with both lung cancer and interstitial lung disease (ILD). This is primarily due to the possible risk of ILD exacerbation caused by surgery or radiotherapy. The current study aimed to investigate the efficacy and safety of local ablative therapy (LAT) for this specific population.

Methods

Consecutive patients with non-small cell lung cancer (NSCLC) and ILD who received LAT between January 2018 and August 2022 were enrolled, and propensity score matching (PSM) was utilized to match the non-ILD group. The primary endpoint was recurrence-free survival (RFS), and secondary endpoints included overall survival (OS), adverse events (AEs) and hospital length of stay (HLOS).

Results

The

SUBMITTER: Shao C 

PROVIDER: S-EPMC10995702 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature